‘’The Alzheimer’s drug lecanemab has received unanimous support from an advisory panel for the US Food and Drug Administration, which deemed it to have ‘clinical benefit’ for the treatment of the disease. This positive vote paves the way for the medication to be considered for full FDA approval.

Lecanemab, known as Leqembi, is one of the first drugs that appears to slow cognitive decline in dementia patients by targeting amyloid beta. Patient groups and experts hope that this milestone decision will ensure access to FDA-approved therapies without barriers, similar to treatments for other serious conditions. The FDA is expected to announce its decision by July 6.’’ 

To read the full article, click here: FDA advisers vote that lecanemab shows benefit as an Alzheimer’s treatment | CNN